基因突变/核心结合因子阴性急性髓性白血病可能是一个复杂的亚组,预后不佳:单中心回顾性分析
Rui Jiang1,2, Zhibo Zhang1,2, Yizi Liu1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
核心结合因子阴性急性髓性白血病 (CBF阴性AML) 的KIT突变表明预后不佳. 这项研究描述了KIT突变/CBF阴性AML,揭示了令人丧的结果,并暗示了向治疗的潜在益处.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 已知核心结合因子 (CBF) AML与KIT突变相关的预后不佳.
- 关于CBF阴性 (CBF阴性) AML中KIT突变的数据有限.
- 了解KIT突变在CBF阴性AML中的作用对于治疗策略至关重要.
研究的目的:
- 描述KIT突变/CBF阴性AML患者的临床特征和结果.
- 为了确定这个AML亚组中常见的共变异.
- 评估KIT突变在CBF阴性AML中的预后影响.
主要方法:
- 通过下一代测序 (NGS) 识别的KIT突变的de novo非M3AML患者的回顾性分析.
- 排除CBF AML和患有全身性巨细胞瘤的患者.
- 收集和分析临床数据,包括突变概况,无事件生存率 (EFS) 和整体生存率 (OS).
主要成果:
- 确定了45名KIT突变/CBF阴性AML患者,其中位数KIT突变变异型等位基因频率 (VAF) 为41.2%.
- 经常发生的共同突变包括CEBPA (60%),WT1 (26.7%) 和NRAS (24.4%).
- 中位数EFS为15.3个月,中位数OS为24.1个月;KIT外型17种突变与较低的存活率相关.
结论:
- 基特突变/CBF阴性AML代表了一个独特的亚组,预后不佳.
- 像CEBPA,WT1和NRAS这样的共同突变在这个队列中很常见.
- 向治疗,可能包括新型氨酸激酶抑制剂 (NTI),可能为这些患者提供治疗益处.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
相关概念视频
Other Factors Affecting Respiration Centers
However, the ability to hold one's breath voluntarily is not limitless. When the CO2 concentration in the blood reaches a critical...
Chemical Factors Affecting Respiration Centers
CO2 has a potent influence on respiration and is strictly regulated....
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
